Johnson & Johnson

Johnson & Johnson

JNJNYSE / NASDAQHealthcareLarge cap

$270.47+$3.33 (+1.2%)

Last close · Data as of Nov 20, 2026

Market cap
$549.3B
P/E
20.5x
EV / EBITDA
14.1x
Revenue
$94.2B
Net margin
28.5%
ROCE
17.6%

+33.2% over the last year

Johnson & Johnson price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+4.3%
3M
+1.2%
6M
+17.9%
1Y
+33.2%
5Y
+66.0%

52-week range

Day change +$3.33 (+1.2%) from $267 to $270 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in JNJ, bought on each weekday since 2021.

News & filings

What Johnson & Johnson filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating profit was 34.6 times interest costs.

Concerns

No concern stands out for this company on the data on file.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech.

Read moreShow less

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Sector
Healthcare
Shares outstanding
2.41B

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$549.3B
P/E
20.5x
P/B
6.7x
EV / EBITDA
14.1x
EV / Sales
6.1x
P/S
5.8x
52-week high
$285.75
52-week low
$199.96

Profitability

Operating margin
27.2%
Net margin
28.5%
EBITDA margin
43.6%
ROE
32.9%
ROCE
17.6%
ROA
13.5%
Asset turnover
0.47

Growth

Revenue
$94.2B
Revenue growth, 1Y
6.0%
Revenue CAGR, 3Y
5.6%
Net profit growth, 1Y
90.6%
Free cash flow
$19.3B

Solvency

Current ratio
1.03
Debt / Equity
0.59
Debt / Assets
0.24
CFO / Net profit
0.92
Cash / Market cap
3.6%

Where the revenue went

Of every $100 of FY2025 revenue, $28 was left as net income.

Johnson & Johnson income statement flow, FY2025
Johnson & Johnson income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$30.3B
RevenueGross profit$63.9B
Gross profitResearch and development$14.7B
Gross profitSelling, general and administrative$23.7B
Gross profitOperating income$25.6B
Operating incomePretax income$25.6B
Interest and other incomePretax income$7.0B
Pretax incomeTax and other$5.8B
Pretax incomeNet income$26.8B

Revenue and net profit

Revenue grew 6.0% in FY2025; net profit is the dashed line.

Johnson & Johnson revenue and net profit by fiscal year
Johnson & Johnson revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$80.0B$17.9B
FY2023$85.2B$35.2B
FY2024$88.8B$14.1B
FY2025$94.2B$26.8B

Cash flows

FY2025: $24.5B from operations, $19.3B free after investment (dashed).

Johnson & Johnson operating and free cash flow by fiscal year
Johnson & Johnson operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$21.2B$17.2B
FY2023$22.8B$17.8B
FY2024$24.3B$18.1B
FY2025$24.5B$19.3B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$94.2B+6.0%1Y
EBITDA
$41.1B+65.7%1Y
Net profit
$26.8B+90.6%1Y
Cash from operations
$24.5B+1.1%1Y
Free cash flow
$19.3B+6.9%1Y
Revenue CAGR, 3Y
5.6%
Net profit CAGR, 3Y
14.3%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$94.2B$41.1B$26.8B$19.3B32.9%+6.0%+90.6%

Monthly returns

Month-by-month returns of JNJ across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$199.2B
Liabilities$117.7B
Equity$81.5B
Paid-in capital$169.0B
Treasury stock$75.6B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; JNJ highlighted.

P/E against peers

JNJ trades at 20.5x earnings against a peer median of 25.5x (a 20% discount).

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Johnson & JohnsonJNJthis companyP/E ↓ discount$549.3B20.5x6.7x32.9%14.1x
AbbVie Inc.ABBV$397.4B94.9x—-128.0%26.1x
UnitedHealth Group IncorporatedUNH$360.1B29.9x3.8x12.8%18.0x
Merck & Co., Inc.MRK$297.0B16.3x5.6x34.7%11.7x
Amgen Inc.AMGN$186.5B24.2x21.5x89.1%13.7x
Thermo Fisher Scientific Inc.TMO$179.1B26.7x3.4x12.6%18.1x
Gilead Sciences, Inc.GILD$160.4B18.8x7.1x37.5%12.9x
Abbott LaboratoriesABT$158.1B24.2x3.0x12.5%13.5x
Intuitive Surgical, Inc.ISRG$148.3B51.9x8.3x16.0%39.3x
Peer median—25.5x5.6x14.4%15.8x

Year-to-date ROI

JNJ since 1 January, against earlier years.

Historical volatility

JNJ's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Johnson & Johnson operating margin by fiscal year
Johnson & Johnson operating margin by fiscal year
DateOperating margin
FY202226.3%
FY202325.8%
FY202423.9%
FY202527.2%
LineFY2025
Cost of revenueCost Of Revenue$30.3B
Gross profitGross Profit$63.9B
Operating expensesOperating Expense$38.3B
Research and developmentResearch And Development$14.7B
Total expensesTotal Expenses$68.6B
Operating incomeOperating Income$25.6B
Pretax incomePretax Income$32.6B

Learn while you research

Academy chapters picked for Johnson & Johnson and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →